uniQure Shares Rally After Replimune Secures FDA Path to Resubmit RP1 BLA
uniQure stock jumped about 20% on Friday following news that Replimune has reached alignment with the U.S. Food and Drug Administration to resubmit a Biologics License Application for RP1 in combination with nivolumab for advanced melanoma. Replimune's shares rose roughly 70% after announcing imminent BLA resubmission, reversing a prior agency reje…